Erasca's ERAS-0015 showed a 44% confirmed objective response rate across 25 patients with KRAS G12X mutations. The Phase 3 trial in first-line pancreatic cancer is accelerated to the first half of 2027.
ERAS · Erasca, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- May 8, 2024
- Latest filing
- 10-Q · Nov 12
- Price history
- Jul 2021 to Nov 2026
Up next
Latest documents
The CEO said the 32 milligram cohort had about seven patients in July and is guided to more than double that. He said 32 milligrams did seem like the most promising dose based on the July data. The CFO said a collaboration with BMS for NABLI metastat, a PRMT5 inhibitor, was announced the previous evening.
Erasca reported that ERAS-0015 received FDA Fast Track Designation for metastatic pancreatic adenocarcinoma, while cash, cash equivalents, and marketable securities totaled $948 million as of September 30, 2026.
ERAS-0015 showed preliminary Phase 1 monotherapy response rates of 62% (N=37) in 2L+ KRAS G12X NSCLC and 75% (N=16) in post-ICI/platinum KRAS G12X NSCLC at 16-32 mg QD.
ERAS plans three registration-enabling studies after raising $632 million in July, with pancreatic phase three initiation in 2027 and lung phase three starts between the second half of 27 and first half of 28.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Gross proceeds from upsized public offering | $632.5M | July 2026 | — |
| Median relative dose intensity | 100% | Q2 2026 | — |
| uORR8wk | 57% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ERAS
this stock
Erasca, Inc.
|
$4.78B | +265.9% | — | — | 10.6% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$130.58B | +13.6% | +46.2% | 33.2 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.24B | +19.3% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$78.90B | +561.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$62.17B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 20, 2026
- This year
- 29
Erasca's ERAS-0015 showed a 44% confirmed objective response rate across 25 patients with KRAS G12X mutations. The Phase 3 trial in first-line pancreatic cancer is accelerated to the first half of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ERAS | -13.1% | -5.4% | +1.0% | -5.2% | +265.9% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -4.5% | +3.8% | +10.1% | +3.6% | +264.7% |